Phase I/II Randomised, Double- Blind, Multi-centre Study to Assess the Efficacy of AZD2281 When Given in Combination With Paclitaxel in the 1st or 2nd Line Treatment of Patients With Metastatic Triple Negative Breast Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 29 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary) ; Paclitaxel
Indications Advanced breast cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors AstraZeneca

Most Recent Events

05 Mar 2018 Status changed from active, no longer recruiting to completed.
29 Nov 2017 Planned End Date changed from 29 Dec 2017 to 28 Dec 2018.
30 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight